Aurinia Pharmaceuticals (AUPH) Misses Q2 EPS by 3c

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q2 EPS of ($0.25), $0.03 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $28.2 million versus the consensus estimate of $27.04 million.

GUIDANCE:

Aurinia Pharmaceuticals sees FY2022 revenue of $115-135 million, versus the consensus of $134.6 million.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• AutoZone (AZO) PT Lowered to $4,230 at UBS Following 'Underwhelming' Q4 Print
• TD Cowen on Alaska Air (ALK): 'Can Alaska ReAccelerate?'